# A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Source: https://onco.cc/trials/nct02320435/  
OnCo record `nct02320435` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pertuzumab and Trastuzumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial is a phase 3 interventional study registered as NCT02320435 by Hoffmann-La Roche, with 154 participants enrolled, started 2015-02-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pertuzumab, Trastuzumab and Other Combination Anti-Cancer Therapies.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02320435
- Phase: 3
- Setting: A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
- Sponsor: Hoffmann-La Roche
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT02320435: https://clinicaltrials.gov/study/NCT02320435

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct02320435.json